about

Group Overview

This year we celebrate our 20th anniversary as a JSE-listed company. Established from humble beginnings in Durban South Africa, and with a 160 year heritage, we have grown into a leading specialty and branded multinational pharmaceutical company. Our extensive basket of high quality, affordable products treat a broad spectrum of acute and chronic conditions experienced through all stages of life.

Our core categories that receive our highest focus include Regional Brands, Anaesthetics, Thrombosis, High Potency & Cytotoxics and Nutritionals.

Our manufacturing capabilities are scaleable to demand and cover a wide variety of product types including injectables, oral solid dose, liquids, semi-solids, steriles, biologicals, active pharmaceutical ingredients and nutritionals. We operate 25 manufacturing facilities across 17 sites and we hold international manufacturing approvals from some of the most stringent global regulatory agencies listed here including, among others, the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines.

GLOBAL PRESENCE

We operate with an established business presence in approximately 70 countries and supply products in more than 150 countries.

Quick Facts

Established: 1850
Employees: + 10 000
Market capitalisation: US$10 billion
Share code: APN
JSE: Top 20 on this exchange 

Board of Directors

Stephen Saad (54)

Stephen Saad (54)

Qualification:
CA(SA), Honorary doctorate
Appointment: January 1999
Classification: Executive director; Aspen Group Chief Executive

Gus Attridge (57)

Gus Attridge (57)

Qualification:
 CA(SA)
Appointment: January 1999
Classification: Executive director; Deputy Group Chief Executive

Kuseni Dlamini (50)

Kuseni Dlamini (50)

Qualification:
 MPhil (Oxon), BSocSci (Hons), (Natal) (see full CV's)
Appointment: April 2012
Classification: Independent non-executive, Chairman

Roy Andersen (70)

Roy Andersen (70)

Qualification:
 CA(SA), CPA (Texas), CD(SA)
Appointment: August 2008
Classification: Lead independent non-executive

Linda de Beer (49)

Linda de Beer (49)

Qualification: 
CA(SA), MCom (Tax), CD(SA)
Appointment: July 2018
Classification: Independent non-executive

Chris Mortimer (57)

Chris Mortimer (57)

Qualification: 
BA, LLB
Appointment: January 1999
Classification: Non-executive

Babalwa Ngonyama (44)

Babalwa Ngonyama (44)

Qualification:
 CA(SA), MBA, Higher Diploma in Banking Law (RAU)
Appointment: April 2016
Classification: Independent non-executive

David Redfern (52)

David Redfern (52)

Qualification: 
BSc (Hons), CA
Appointment: February 2015
Classification:Non-executive (British)

Sindi Zilwa (51)

Sindi Zilwa (51)

Qualification:
 CA(SA), CDSA, Advanced Taxation (UNISA) Certificate (see CV's)
Appointment: September 2006
Classification: Independent non-executive

Business Segment Overview

REGIONAL

regional
pg-5-sml-icon-1

Revenue

R14 336 million

34%

of total revenue

KEY BRANDS
  • Circadin
  • Foxair
  • Mybulen
  • Tribuss
  • Zyloric

Anaesthetics

anaesthetics
pg-5-sml-icon-2

Revenue

R8 332 million

19%

of total revenue

KEY BRANDS
  • Diprivan
  • EMLA
  • Naropin
  • Ultiva
  • Xylocaine

THROMBOSIS

thrombosis
pg-5-sml-icon-4

Revenue

R6 430 million

15%

of total revenue

KEY BRANDS
  • Arixtra
  • Fraxiparine
  • Fraxodi
  • Mono-embolex
  • Orgaran

HIGH POTENCY & CYTOTOXICS

cytoxins
pg-5-sml-icon-3

Revenue

R4 172 million

10%

of total revenue

KEY BRANDS
  • Alkeran
  • Eltroxin
  • Imuran
  • Ovestin
  • Purinethol

NUTRITIONALS

nutritionals
nutritionals-icon

Revenue

R3 091 million

7%

of total revenue

KEY BRANDS
  • Alula
  • Infacare